Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why - MarketWatch

Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why  MarketWatch

Shares of Belgium-based biotech Galapagos NV soared 23% on Friday after the company, together with pharmaceutical giant Gilead Sciences Inc., announced.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases